Clinical trial
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
NCT00046696 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00046696 |
|---|---|
| Title | A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. |
| Official title | A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | NM-3 |
| Enrollment | 32 |
| Start date | May 1, 2001 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Oct 2, 2002 |
| Last update posted | May 20, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: